Journal article
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study
Abstract
BACKGROUND: Treatment of venous thromboembolism (VTE) in patients with cancer has a high rate of recurrence and bleeding complications. Guidelines recommend low-molecular-weight heparin (LMWH) for at least 3-6 months and possibly indefinitely for patients with active malignancy. There are, however, few data supporting treatment with LMWH beyond 6 months. The primary aim of the DALTECAN study (NCT00942968) was to determine the safety of …
Authors
Francis CW; Kessler CM; Goldhaber SZ; Kovacs MJ; Monreal M; Huisman MV; Bergqvist D; Turpie AG; Ortel TL; Spyropoulos AC
Journal
Journal of Thrombosis and Haemostasis, Vol. 13, No. 6, pp. 1028–1035
Publisher
Elsevier
Publication Date
June 2015
DOI
10.1111/jth.12923
ISSN
1538-7933